Moreover, the combination of the SHP-2 inhibitor and the G12C inhibitor modulates the immune microenvironment of the tumor via reducing myeloid suppressor cells and increasing CD8+ T cells, leading to tumor sensitivity to PD-1 (programmed death 1) receptor blockade [68]. The gene discussed is PDCD1; the disease is neoplasm.